glutathione S-transferase mu 4Genealiases: GSTM4-4 · GTM4
Q-omics provides the consensus-scored GSTM4 profile across patient tissues and cancer cell-line models. GSTM4 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, GSTM4 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, GSTM4 RNA expression shows 15,614 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BRCA, COAD, and LSCC as cancer lineages where GSTM4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GSTM4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GSTM4 survival associations across molecular data types. GSTM4 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GSTM4 RNA expression–survival associations across cancer types. High GSTM4 expression shows unfavorable associations in LGG and ACC, but favorable associations in BRCA, READ, CESC and MESO. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for GSTM4 RNA expression.
This table summarizes GSTM4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for GSTM4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GSTM4 shows lower tumor expression in COAD, KICH, THCA, UCEC and BRCA and higher tumor expression in LIHC. The COAD box plot shows higher GSTM4 RNA expression in normal versus tumor tissue (log2 FC = −1.025, t-test p < 0.001).
This table shows molecular features associated with GSTM4 in patient tissues and cancer cell lines. In patient samples, GSTM4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GSTM4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
